ReviewFrontiers in cellular and infection microbiology2023
Review in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Mesenchymal stem cell-derived conditioned medium demonstrates novel antibacterial effects in ocular bacterial infections.Infection and immunity · 2026Article
- A sustained living coating for infectious keratitis therapy via probiotic consumption and production effects.Science advances · 2026Article
- Parameter-Dependent Effects of Rose Bengal Photodynamic Antimicrobial Therapy on MRSA Inhibition and Corneal Cytokine Expression.Translational vision science & technology · 2026Article
- Potential of isoquinoline-alkaloid-richFrontiers in pharmacology · 2026Article
- Vaccines for microbial eye diseases in the era of data science: opportunities and challenges.Frontiers in immunology · 2026Review
- Structural and functional insights into Pseudomonas aeruginosa's secretion systems 1-6: regulation, role in microbial keratitis and drug targets.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- α-hemolysin polymorphisms in methicillin-resistantbioRxiv : the preprint server for biology · 2025Article
- Microbial keratitis in the age of resistance: unlocking the therapeutic potential of phage therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- AZD6738 Attenuates LPS-Induced Corneal Inflammation and Fibrosis by Modulating Macrophage Function and Polarization.Inflammation · 2025Article
- Invasomes and Nanostructured Lipid Carriers for Targeted Delivery of Ceftazidime Combined with N-Acetylcysteine: A Novel Approach to TreatPharmaceutics · 2025Article
- Wearing bacteriophages individually with an adhesive drug-loadable nanohelmet for treating ocular infections.Science advances · 2025Article
- Factors Associated with Vision Outcomes in Microbial Keratitis: A Multisite Prospective Cohort Study.Ophthalmology · 2025Article
- TRPV1 Defends the Healthy Murine Cornea Against Staphylococcus aureus Adhesion Independently of Sensory Nerve Firing.Investigative ophthalmology & visual science · 2025Article
- An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.Journal of nanobiotechnology · 2025Review
- Review
- A Label-Free Fluorescent Amplification Strategy for High-Sensitive Detection ofJournal of microbiology and biotechnology · 2024Article
- Investigating the Bactericidal Activity of an Ocular Solution Containing EDTA, Tris, and Polysorbate 80 and Its Impact on the In Vitro Efficacy of Neomycin Sulfate againstAntibiotics (Basel, Switzerland) · 2024Article
- Rutin/Sulfobutylether-β-Cyclodextrin as a Promising Therapeutic Formulation for Ocular Infection.Pharmaceutics · 2024Article
- Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Infectious Keratitis.Journal of ophthalmology · 2024Article
- Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-ResistantOphthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial keratitis (bacterial infection of the cornea) is a major cause of vision loss worldwide. Given the rapid and aggressive nature of the disease, immediate broad-spectrum antibiotics are essential to adequately treat this disease. However, rising antibiotic resistance continues to accelerate, rendering many commonly used therapeutics increasingly ineffective. As such, there is a significant effort to understand the basic pathogenesis of common causative organisms implicated in keratitis in part, to fuel the development of novel therapies to treat this blinding disease. This review explores two common causes of bacterial keratitis,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.